Product Information
BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.6628 per EA under NDC 00054018913. Its NADAC has been published 634 times since Aug 13, 2014.
FDA first approved this application on Jun 27, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET
buprenorphine hydrochloride and naloxone hydrochloride dihydrateStrength
8; 2 mg/1; mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054018913
Classification
Generic
Dosage Form
TABLET
Route
SUBLINGUAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE DIHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA203326FDA Approved
6/27/2014
TE Code
AB
On Market Since
6/27/2014
Pharmacological Classes
Price Statistics
The NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has been published 634 times since Aug 13, 2014, and over the history we have for it it has declined 89.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6628 per EA |
|---|---|
| All-time high | $6.1950 (Aug 13, 2014) |
| All-time low | $0.6322 (Jul 22, 2026) |
| 52-week high | $0.7191 |
| 52-week low | $0.6322 |
| Median price | $1.3035 |
| Average price | $2.2462 |
| Largest weekly change | +29.6% (Aug 21, 2024) |
| Weeks tracked | 634 |
| Tracking since | Aug 13, 2014 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
buprenorphine hydrochloride and naloxone hydrochloride dihydrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET, manufactured by Hikma Pharmaceuticals USA Inc., is $0.6628 per EA (NDC 00054018913), effective Sep 30, 2026.
How has the price of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET changed over time?
Over the history we have for it, the NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has declined 89.3%. It has been tracked across 634 weekly CMS publications since Aug 13, 2014.
What are the highest and lowest recorded NADAC prices for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?
Since Aug 13, 2014, the NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has ranged from a low of $0.6322 (Jul 22, 2026) to a high of $6.1950 (Aug 13, 2014), with a median of $1.3035 per EA.
Are there cheaper alternatives to BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?
BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET (NDC 00054018913) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.